Evaluation of in vitro chemoresponse profiles in @entity1 with XXXX : An observational study ancillary analysis.

@entity43 @entity1 @entity5 @entity3907 @entity196 @entity902
OBJECTIVE: Type @entity43 (EOCs) are reported to be relatively chemoresistant. This study sought to compare pretreatment chemoresponse assays in @entity196 vs. Type II EOCs. STUDY DESIGN: 383 @entity1 with stage III-IV EOC enrolled in an observational study, with known chemoresponse assay results for 7 common therapeutic agents, were included. @entity196 EOCs were defined as grade 1 serous/endometrioid @entity5 and all @entity5 . Type II EOCs were classified as grade 2-3 serous/endometrioid @entity5 and undifferentiated @entity5 . Chemotherapy assay responses were classified as sensitive (S), intermediately sensitive (I), or resistant (R). All @entity1 were treated with @entity902 / @entity3907 therapy following cytoreductive surgery. RESULTS: Thirty (7.8%) @entity5 were classified as @entity196 EOC, and 353 (92.2%) as Type II EOC. @entity196 @entity1 were younger at the time of diagnosis (median age: 57 vs. 62 years, p=0.018) and had longer survival compared to Type II @entity1 (mPFS: 25.8 vs. 16.4 months, HR=1.71, p=0.042). Eighty-six percent of @entity196 EOC specimens demonstrated a sensitive chemoresponse assay result to at least 1 agent; 35.7% were pan-S to all 7 agents. After adjusting for stage, debulking status, and type of EOC, multi-drug resistance was twice as likely in @entity1 with @entity196 EOC compared to Type II EOC (pan-R, 14.3% vs. 6.8% (p=0.268); pan-S, 35.7% vs. 51.2% (p=0.183)), but did not attain statistical significance. CONCLUSION(S): The majority of @entity1 with @entity196 EOC displayed assay sensitivity to at least one agent. Given the small sample size these findings need to be evaluated further.
